Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

Fig. 1

Atrasentan reduces insulin resistance. Panel A: Change from baseline in HOMA-IR in the RADAR trial. Panel B: Geometric mean HOMA-IR values per study visit in the SONAR trial. During the enrichment period of the SONAR trial all patients received atrasentan 0.75 mg/day. Enrichment results of patients subsequently randomized to continue atrasentan or to transition to placebo are presented separately

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840